ZURICH, Aug 27 (Reuters) - Swiss drugmaker Novartis AG NOVN.VX said on Monday its Rasilez high blood pressure treatment had been approved for use in the European Union.
Rasilez, which is known as Tekturna in the United States and was co-developed by Swiss biotech company Speedel SPPN.S, is already approved in the United States and Switzerland.
The EU approval had been expected after Rasilez was recommended by a European panel of experts.
((Reporting by Sam Cage, Email: email@example.com
Telephone: +41 (0) 44 631 7457)) Keywords: SPEEDEL RASILEZ/
C Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEB6853